Kasuo Miyake, MD-PhD, is one of the world’s leading vascular surgeons, respected for his contribution to the development of new techniques for different types of varicose vein treatment. Based on his doctoral thesis, he created the CLaCS technique along with his father, and pioneered the use of augmented reality, like VeinViewer‘s near-infrared technology, in the treatment of micro spider veins and varicose veins.
Recognized for researching new technologies and improving techniques for a modern treatment of varicose veins, Dr. Miyake has a specialization in Angiology and Vascular Surgery at the Hospital das Clínicas, Faculty of Medicine, USP and by the Brazilian Society of Angiology and Vascular Surgery.
Anteris Technologies (AVR) pauses trading as it plans for an upcoming capital raise
On Thursday, the company entered a trading halt, pausing shares until Monday, August 2
It is unknown how much the company is planning to raise or where the funds will be spent
On the market, Anteris last traded at $8.59 per share
Anteris Technologies (AVR) has paused trading as it plans for an upcoming capital raise.
On Thursday, the company entered a trading halt, pausing shares until Monday, August 2.
Currently, it is...
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant, or BEI, for severe esophageal disease including cancer, today announced its financial results for the three months ended March 31, 2022, and highlighted recent events.
The Company will be hosting a conference...
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). The FDA’s Breakthrough Device designation is designed to expedite the development and review of medical devices that are intended to treat serious or life-threatening diseases. To qualify for this designation,...
Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for the on-going clinical trial, ASPIRE, for P-15L Bone Graft in a single level transforaminal lumbar interbody fusion (TLIF) surgery.
“We are pleased to announce FDA approval of an IDE supplement resulting in a reduction of the total number of patients required to be enrolled in...
Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a statistically significantly higher fusion rate compared to allograft plus local bone.
“In Scandinavia,...
Customer comments
No comments were found for Discover Dr. Kasuo Miyake’s Innovative CLaCS Procedure. Be the first to comment!
